RYTM Form 4 reports acquisition/exercise transactions

German Christopher Paul reported acquisition or exercise transactions in a Form 4 filing for RYTM.

Accepted by SEC EDGAR 02/13/2026 - 05:48 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

German Christopher Paul reported acquisition or exercise transactions in a Form 4 filing for RYTM. The filing lists transactions totaling 5,215 shares. Following the reported transactions, holdings were 5,215 shares.

Insider Trade Summary

Grant/Award: 5,215 shares

Grant/Award 1 txn

Insider German Christopher Paul

Role Corporate Controller & CAO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	5,215	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 5,215 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
2. F2. The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Rhythm Pharmaceuticals (RYTM) report on this Form 4?

Rhythm Pharmaceuticals reported that Corporate Controller & CAO Christopher Paul German received a grant of 5,215 restricted stock units on February 11, 2026. This was an equity award, not an open-market trade, and is recorded as a direct ownership position.

How many restricted stock units were granted to Christopher Paul German at Rhythm Pharmaceuticals (RYTM)?

Christopher Paul German was granted 5,215 restricted stock units. Each unit represents the contingent right to receive one share of Rhythm Pharmaceuticals common stock, recorded at a transaction price of $0 per unit as part of his equity compensation package.

What is the vesting schedule for the 5,215 RSUs at Rhythm Pharmaceuticals (RYTM)?

The 5,215 restricted stock units vest in four equal installments of 25% each. Vesting occurs on February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030, subject to the award’s terms and continued eligibility conditions.

Does the RSU award to the Rhythm Pharmaceuticals (RYTM) officer have an expiration date?

The restricted stock unit award has no expiration date. Instead, the units become shares over time according to the vesting schedule, with 25% vesting on each of February 1, 2027, 2028, 2029 and 2030, assuming vesting conditions are satisfied.

Is the Form 4 transaction for Rhythm Pharmaceuticals (RYTM) an acquisition or a sale?

The Form 4 reports an acquisition transaction. It is coded as a grant, award, or other acquisition of derivative securities, reflecting 5,215 restricted stock units being awarded to the officer rather than any sale or disposal of existing holdings.

How is ownership of the new RSUs at Rhythm Pharmaceuticals (RYTM) classified on the Form 4?

Ownership of the 5,215 restricted stock units is classified as direct. The filing indicates the officer directly holds these derivative securities, which are tied to Rhythm Pharmaceuticals common stock, subject to the four-year, 25%-per-year vesting schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

German Christopher Paul

(Last) (First) (Middle)

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Corporate Controller & CAO

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/11/2026		A		5,215		(2)	(2)	Common Stock	5,215	$0	5,215	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

2. The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.

	/s/ Stephen Vander Stoep, attorney-in-fact for Christopher Paul German	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.